Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7469737rdf:typepubmed:Citationlld:pubmed
pubmed-article:7469737lifeskim:mentionsumls-concept:C0002688lld:lifeskim
pubmed-article:7469737lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:7469737lifeskim:mentionsumls-concept:C0872916lld:lifeskim
pubmed-article:7469737lifeskim:mentionsumls-concept:C0036576lld:lifeskim
pubmed-article:7469737lifeskim:mentionsumls-concept:C0449297lld:lifeskim
pubmed-article:7469737lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:7469737lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:7469737pubmed:issue1lld:pubmed
pubmed-article:7469737pubmed:dateCreated1981-4-13lld:pubmed
pubmed-article:7469737pubmed:abstractTextXenon Xe 133 clearance was used to select the most distal amputation level that would allow sufficient blood flow for healing. Capillary blood flow was first measured at the most distal potential amputation level, then at successive proximal levels until an amputation site was found that had a capillary skin blood flow rate greater than or equal to 2.6 mL/min/100 g of tissue. Xenon Xe 133 in saline (100 to 500 mCi) was injected intracutaneously at each level, and flow rates were determined using a gamma camera interfaced with a computer system programmed for the Ketty-Schmidt formula modified for capillary blood flow. There were 45 cases, including one toes, six transmetatarsal, five Syme's, 25 below-knee, four knee disarticulation, three above-knee, and one hip disarticulation amputation. All amputations in patients with flow rates exceeding 2.4 mL/min/100 g of tissue healed, with two exceptions.lld:pubmed
pubmed-article:7469737pubmed:languageenglld:pubmed
pubmed-article:7469737pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7469737pubmed:citationSubsetAIMlld:pubmed
pubmed-article:7469737pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7469737pubmed:statusMEDLINElld:pubmed
pubmed-article:7469737pubmed:monthJanlld:pubmed
pubmed-article:7469737pubmed:issn0004-0010lld:pubmed
pubmed-article:7469737pubmed:authorpubmed-author:GaleA MAMlld:pubmed
pubmed-article:7469737pubmed:authorpubmed-author:MooreW SWSlld:pubmed
pubmed-article:7469737pubmed:authorpubmed-author:MaloneJ MJMlld:pubmed
pubmed-article:7469737pubmed:authorpubmed-author:HenryR ERElld:pubmed
pubmed-article:7469737pubmed:authorpubmed-author:PattonDDlld:pubmed
pubmed-article:7469737pubmed:authorpubmed-author:ChildersS JSJlld:pubmed
pubmed-article:7469737pubmed:issnTypePrintlld:pubmed
pubmed-article:7469737pubmed:volume116lld:pubmed
pubmed-article:7469737pubmed:ownerNLMlld:pubmed
pubmed-article:7469737pubmed:authorsCompleteYlld:pubmed
pubmed-article:7469737pubmed:pagination86-8lld:pubmed
pubmed-article:7469737pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7469737pubmed:meshHeadingpubmed-meshheading:7469737-...lld:pubmed
pubmed-article:7469737pubmed:meshHeadingpubmed-meshheading:7469737-...lld:pubmed
pubmed-article:7469737pubmed:meshHeadingpubmed-meshheading:7469737-...lld:pubmed
pubmed-article:7469737pubmed:meshHeadingpubmed-meshheading:7469737-...lld:pubmed
pubmed-article:7469737pubmed:meshHeadingpubmed-meshheading:7469737-...lld:pubmed
pubmed-article:7469737pubmed:meshHeadingpubmed-meshheading:7469737-...lld:pubmed
pubmed-article:7469737pubmed:meshHeadingpubmed-meshheading:7469737-...lld:pubmed
pubmed-article:7469737pubmed:meshHeadingpubmed-meshheading:7469737-...lld:pubmed
pubmed-article:7469737pubmed:meshHeadingpubmed-meshheading:7469737-...lld:pubmed
pubmed-article:7469737pubmed:meshHeadingpubmed-meshheading:7469737-...lld:pubmed
pubmed-article:7469737pubmed:meshHeadingpubmed-meshheading:7469737-...lld:pubmed
pubmed-article:7469737pubmed:year1981lld:pubmed
pubmed-article:7469737pubmed:articleTitleProspective use of xenon Xe 133 clearance for amputation level selection.lld:pubmed
pubmed-article:7469737pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7469737pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed